Unveiling the Heart's Dilemma: Which Prostate Cancer Treatment is Safer?
The Core Issue: Androgen deprivation therapy (ADT) is a common treatment for localized prostate cancer, but it poses a significant risk to the heart. The question arises: which type of ADT is safer for the heart?
The Study: A small, randomized trial compared the effects of leuprolide and relugolix, two types of ADT, on coronary artery disease progression in men with nonmetastatic prostate cancer. The results were striking.
The Findings: Men treated with leuprolide experienced significantly faster progression of coronary artery disease compared to those on relugolix. This was driven by changes in noncalcified plaque volume, which are less stable and strongly associated with heart attacks. Interestingly, testosterone levels declined at months 3 and 6, with no significant differences between the two groups, suggesting that the cardiovascular effect of ADT may be unrelated to the magnitude of testosterone suppression.
The Takeaway: The study authors concluded that the cardiovascular effect of ADT is detectable in the near term and is drug pathway-specific, independent of testosterone suppression. This is the first study to identify a biological basis for the differing cardiovascular risks associated with different ADT types.
The Controversy: The study raises important questions about the safety of different ADT treatments. While leuprolide has been linked to faster coronary artery disease progression, relugolix appears to carry lower cardiovascular risks. However, the study's limitations, such as the small sample size and the presence of coronary disease in most patients at baseline, may limit its generalizability to healthier populations.
The Call to Action: What do you think? Do you agree with the study's findings? Or do you have a different interpretation? Share your thoughts in the comments below!
